Overview of JNC VI: New directions in the management of hypertension and cardiovascular risk

American Journal of Hypertension

Volumn 12, Issue 8 SUPPL. 1, 1999, Pages 65S-72S

  Sheps, Sheldon G ^a,b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Antihypertensive therapy; Cardiovascular risk factors; Hypertension; Lifestyle modification

Indexed keywords

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CONFERENCE PAPER; DIET THERAPY; HUMAN; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETES COMPLICATIONS; DIET; FEMALE; HUMANS; HYPERTENSION; LIFE STYLE; MALE; MIDDLE AGED; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0032869893     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(99)00111-9     Document Type: Review

References (20)

1. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI): The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
2. Burt VL, Cutler JA, Higgins M, et al: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-69.
3. Burt VL, Whelton P, Roccella EJ, et al: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-313.
4. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-183.
5. Levy D, Larson MG, Vasan RS, et al: The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-1562.
6. Office of Disease Prevention and Health Promotion. Healthy People 2000 Midcourse Review and 1995 Revisions http://odphp.osophs.dhhs.gov/pubs/hp2000/midcours. htm Posted January 12, 1999.
7. Meissner I, Whisnant JP, Sheps S, et al: Stroke prevention: assessment of risk in a community. The SPARC study, part I: blood pressure trends, treatment, and control (abstr). Ann Neurol 1997;42:433.
8. Brown RD Jr, Whisnant JP, Sicks JD, et al: Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-380.
9. Luepker RV, McGovern PG, Sprafka JM, et al: Unfavorable trends in the detection and treatment of hypertension: the Minnesota Heart Survey (abstr). Circulation 1995;91:938.
10. Joffres MR, Ghadirian P, Fodor JG, et al: Awareness, treatment and control of hypertension in Canada. Am J Hypertens 1997;10:1097-1102.
11. NHLBI Clinical Guidelines on the Identification, Evaluation and Treatment of Obesity in Adults. 1998;1. http://www.nhlbi.nih.gov/nhlbi/cardio/obes/prof/guidelns/ ob_home.htm.
12. Personal Communication, Cushman W, ASH annual meeting, 1997.
13. NHLBI Working Group: Management of patient compliance in the treatment of hypertension. Report of the NHLBI Working Group. Hypertension 1982;4:415-423.
14. Berlowitz DR, Ash AS, Hickey EC, et al: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1957-1963.
15. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
16. Statistical rolodex. Centers for Disease Control and Prevention. http://www.cdc.gov/nchswww/fastats/overwt.htm http://www.cdc.gov/nchswww/fastats/smoking.htm http:// www.cdc.gov/nchswww/fastats/alcohol.htm Posted January 15, 1999.
17. Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-1762.
18. Parving HH: Is antihypertensive treatment the same for NIDDM and IDDM patients? Diabetes Res Clin Pract 1998;39(suppl):S43-S47.
19. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. (UKPDS 39). Br Med J 1998;317:713-720.
20. Hansson L, Hedner T, Lindholm LH, et al for CAPPP Study Group: The Captopril Prevention Project (CAPPP) in hypertension - final results. J Hypertens 1998;16(suppl 2):S22.